CRISPR Therapeutics
CRSP
CRSP
445 hedge funds and large institutions have $3.25B invested in CRISPR Therapeutics in 2021 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 161 increasing their positions, 128 reducing their positions, and 95 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
6% less funds holding
Funds holding: 471 → 445 (-26)
20% less first-time investments, than exits
New positions opened: 76 | Existing positions closed: 95
28% less capital invested
Capital invested by funds: $4.52B → $3.25B (-$1.27B)
Holders
445
Holding in Top 10
4
Calls
$219M
Puts
$202M
Top Buyers
| 1 | +$114M | |
| 2 | +$81.7M | |
| 3 | +$78.8M | |
| 4 |
Renaissance Technologies
New York
|
+$43.9M |
| 5 |
AC
Armistice Capital
New York
|
+$38.8M |
Top Sellers
| 1 | -$74.5M | |
| 2 | -$68.6M | |
| 3 | -$44.4M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$28.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$28.4M |